BIOLINERX
Careers | Contact Us
search

Press Releases
July 30, 2013
Management to hold a conference call at 10:00 a.m. EDT
July 29, 2013
Study expected to begin in Q4 2013
Results expected in mid-2014
June 10, 2013
BL-8030 is a pre-clinical, second-generation NS3 protease inhibitor
CTTQ receives development and commercialization rights in China and Hong Kong
April 30, 2013
Management to hold conference call at 10:00 a.m. EDT
201-210  Out of  309 Previous
 1   2   3   4   5   6   7   8   9   10   11   12   13   14   15 
 16   17   18   19   20   21   22   23   24   25   26   27   28   29 
 30   31 
Next